Paraoxonase 1 (PON1) 55 polymorphism, lipid profiles and psoriasis

British Journal of Dermatology

Volumn 167, Issue 6, 2012, Pages 1279-1286

  Asefi, M ^a   Vaisi Raygani, A ^a,b   Bahrehmand, F ^a   Kiani, A ^d   Rahimi, Z ^a,c   Nomani, H ^a   Ebrahimi, A ^a   Tavilani, H ^e   Pourmotabbed, T ^f  

^a KERMANSHAH UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^b KERMANSHAH UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^c KERMANSHAH UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^d SHAHID BEHESHTI UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^e HAMADAN UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^f UNIVERSITY OF TENNESSEE HEALTH SCIENCE CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

APOLIPOPROTEIN A1; APOLIPOPROTEIN B; ARYLDIALKYLPHOSPHATASE 1; ARYLESTERASE; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LEUCINE; LOW DENSITY LIPOPROTEIN CHOLESTEROL; MALONALDEHYDE; METHIONINE; TRIACYLGLYCEROL;

ADOLESCENT; ADULT; ARTICLE; CARDIOVASCULAR DISEASE; CLINICAL FEATURE; CONTROLLED STUDY; DISEASE COURSE; DNA POLYMORPHISM; ENZYME ACTIVITY; FEMALE; GENE FREQUENCY; GENETIC ASSOCIATION; HETEROZYGOTE; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; IRAN; LIPID METABOLISM; MAJOR CLINICAL STUDY; MALE; OXIDATIVE STRESS; PATHOGENESIS; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; PSORIASIS; RESTRICTION FRAGMENT LENGTH POLYMORPHISM; RISK FACTOR;

ADOLESCENT; ADULT; AGED; ALLELES; ARYLDIALKYLPHOSPHATASE; BIOLOGICAL MARKERS; CARBOXYLIC ESTER HYDROLASES; CASE-CONTROL STUDIES; CHOLESTEROL, HDL; CHOLESTEROL, LDL; FEMALE; HUMANS; LIPID PEROXIDATION; MALE; MALONDIALDEHYDE; MIDDLE AGED; OXIDATIVE STRESS; POLYMERASE CHAIN REACTION; POLYMORPHISM, RESTRICTION FRAGMENT LENGTH; POLYMORPHISM, SINGLE NUCLEOTIDE; PSORIASIS; RISK FACTORS; TRIGLYCERIDES; YOUNG ADULT;

EID: 84870179338     PISSN: 00070963     EISSN: 13652133     Source Type: Journal    
DOI: 10.1111/j.1365-2133.2012.11170.x     Document Type: Article

References (43)

1. Humbert R, Adler DA, Disteche CM, et al. The molecular basis of the human serum paraoxonase activity polymorphism. Nat Genet 1993; 3: 73-6.
2. Aviram M, Rosenblat M, Billecke S, et al. Human serum paraoxonase (PON1) is inactivated by oxidized low density lipoprotein and preserved by antioxidants. Free Radic Biol Med 1999; 26: 892-904.
3. La Du BN,. Structural and functional diversity of paraoxonases. Nat Med 1996; 2: 1186-87.
4. Reddy ST, Wadleigh DJ, Grijalva V, et al. Human paraoxonase-3 is an HDL-associated enzyme with biological activity similar to paraoxonase-1 protein but is not regulated by oxidized lipids. Arterioscler Thromb Vasc Biol 2001; 21: 542-7.
5. Toker A, Kadi M, Yildirim AK, et al. Serum lipid profile paraoxonase and arylesterase activities in psoriasis. Cell Biochem Funct 2009; 27: 176-80.
6. Aviram M,. Does paraoxonase play a role in susceptibility to cardiovascular disease? Mol Med Today 1999; 5: 381-6.
7. Vaisi-Raygani A, Ghaneialvar H, Rahimi Z, et al. Paraoxonase Arg 192 allele is an independent risk factor for three-vessel stenosis of coronary artery disease. Mol Biol Rep 2011; 38: 5421-8.
8. Mackness B, Mackness MI, Arrol S, et al. Effect of the human serum PON1 55 and 192 genetic polymorphisms on the protection by high density lipoprotein against low density lipoprotein oxidative modification. FEBS Lett 1998; 423: 57-60.
9. Gupta N, Gill K, Singh S,. Paraoxonases: structure, gene polymorphism & role in coronary artery disease. Indian J Med Res 2009; 130: 361-8.
10. Zama T, Murata M, Matsubara Y, et al. A 192Arg variant of the human paraoxonase (HUMPONA) gene polymorphism is associated with an increased risk for coronary artery disease in the Japanese. Arterioscler Thromb Vasc Biol 1997; 17: 3565-9.
11. Pfohl M, Koch M, Enderle MD, et al. Paraoxonase 192 Gln/Arg gene polymorphism, coronary artery disease, and myocardial infarction in type 2 diabetes. Diabetes 1999; 48: 623-7.
12. Koubaa N, Nakbi A, Hammami S, et al. Association of homocysteine thiolactonase activity and PON1 polymorphisms with the severity of acute coronary syndrome. Clin Biochem 2009; 42: 771-6.
13. Hashemi M, Moazeni-Roodi AK, Fazaeli A, et al. The L55M polymorphism of paraoxonase-1 is a risk factor for rheumatoid arthritis. Genet Mol Res 2010; 9: 1735-41.
14. Ferretti G, Bacchetti T, Campanati A, et al. Correlation between lipoprotein(a) and lipid peroxidation in psoriasis: role of the enzyme paraoxonase-1. Br J Dermatol 2012; 166: 204-7.
15. Ortonne JP,. Recent developments in the understanding of the pathogenesis of psoriasis. Br J Dermatol 1999; 140: 1-7.
16. Griffiths CE, Barker JNW,. Pathogenesis and clinical features of psoriasis. Lancet 2007; 360: 263-71.
17. Gottieb AB, Chao C, Dann F,. Psoriasis comorbidities. J Dermatol Treat 2008; 19: 5-21.
18. Christophers E,. Comorbidities in psoriasis. Clin Dermatol 2007; 25: 529-34.
19. Pietrzak A, Lecewicz-Torun B,. Activity of serum lipase [EC 3.1.1.3] and the diversity of serum lipid profiles in psoriasis. Med Sci Monit 2002; 8: 9-13.
20. Armstrong AW, Armstrong EJ, Fuller EN, et al. Smoking and pathogenesis of psoriasis: a review of oxidative, inflammatory and genetic mechanisms. Br J Dermatol 2011; 165: 1162-8.
21. Rocha-Pereira P, Santos-Silva A, Rebelo I, et al. Dislipidemia and oxidative stress in mild and in severe psoriasis as a risk for cardiovascular disease. Clin Chim Acta 2001; 303: 33-39.
22. Vanizor Kural B, Orem A, Cimit G, et al. Evaluation of the atherogenic tendency of lipids and lipoprotein content and their relationships with oxidant-antioxidant system in patients with psoriasis. Clin Chim Acta 2003; 328: 71-82.
23. Mallbris L, Granath F, Hamsten A, Stahle M,. Psoriasis is associated with lipid abnormalities at the onset of skin disease. J Am Acad Dermatol 2006; 54: 614-21.
24. Willerson JT, Ridker PM,. Inflammation as a cardiovascular risk factor. Circulation 2004; 109: II2-10.
25. Ivanova IP, Mareeva TE,. Disorders of lipid peroxidation and of lysosomal hydrolase activity and their correction in psoriasis patients. Vestn Dermatol Venereol 1987; 4: 26-31.
26. Simonetti O, Ferretti G, Salvi A, et al. Plasma lipid changes in psoriatic children. Dermatology 1992; 185: 96-100.
27. Yildirim M, Inaloz HS, Baysal V, Delibas N,. The role of oxidants and antioxidants in psoriasis. J Eur Acad Dermatol Venereol 2003; 17: 34-6.
28. Seishima M, Seishima M, Mori S, Noma A,. Serum lipid and apolipoprotein levels in patients with psoriasis. Br J Dermatol 1994; 130: 738-2.
29. Campalani E, Allen MH, Fairhurst D, et al. Apolipoprotein E gene polymorphisms are associated with psoriasis but do not determine disease response to acitretin. Br J Dermatol 2006; 154: 345-52.
30. Severin E, Nave B, Ständer M, et al. Total antioxidative capacity is normal in sera from psoriasis patients despite elevated bilirubin, tocopherol and urate levels. Dermatology 1999; 198: 336-9.
31. Hubbs L, Psoriasis update. Skin & Aging. Available at: http://www.natbiocorp.com/pdfs/at-home-UVB-therapy.pdf (last accessed 2 August 2012).
32. Kreft S, Kreft M, Resman A, et al. Computer-aided measurement of psoriatic lesion area in a multicenter clinical trial-comparison to physician's estimations. J Dermatol Sci 2006; 44: 21-7.
33. Langley RG, Ellis CN,. Evaluating psoriasis with Psoriasis Area and Severity Index, Psoriasis Global Assessment, and Lattice System Physician's Global Assessment. J Am Acad Dermatol 2004; 51: 563-9.
34. Hasselwander O, Savage DA, McMaster D, et al. Paraoxonase polymorphisms are not associated with cardiovascular risk in renal transplant recipients. Kidney Int 1999; 56: 289-98.
35. Eckerson HW, Wyte CM, La Du BN,. The human serum paraoxonase/arylesterase polymorphism. Am J Hum Genet 1983; 35: 1126-38.
36. Agarwal R, Chase SD,. Rapid, fluorimetric-liquid chromatographic determination of malondialdehyde in biological samples. J Chromatogr B Analyt Technol Biomed Life Sci 2002; 775: 121-6.
37. Raygani AV, Rahimi Z, Kharazi H, et al. Association between apolipoprotein E polymorphism and serum lipid and apolipoprotein levels with Alzheimer's disease. Neurosci Lett 2006; 408: 68-72.
38. Mastorikou M, Mackness B, Liu Y, Mackness M,. Glycation of paraoxonase-1 inhibits its activity and impairs the ability of high-density lipoprotein to metabolize membrane lipid hydroperoxides. Diabet Med 2008; 25: 1049-55.
39. Usta M, Turan E, Aral H, et al. Serum paraoxonase-1 activities and oxidative status in patients with plaque-type psoriasis with/without metabolic syndrome. J Clin Lab Anal 2011; 25: 289-95.
40. Garin MC, James RW, Dussoix P, et al. Paraoxonase polymorphism Met-Leu54 is associated with modified serum concentrations of the enzyme. A possible link between the paraoxonase gene and increased risk of cardiovascular disease in diabetes. J Clin Invest 1997; 99: 62-66.
41. Mackness B, Durrington P, McElduff P, et al. Low paraoxonase activity predicts coronary events in the Caerphilly Prospective Study. Circulation 2003; 107: 2775-79.
42. Watson AD, Berliner JA, Hama SY, et al. Protective effect of high density lipoprotein associated paraoxonase: inhibition of the biological activity of minimally oxidized low density lipoprotein. J Clin Invest 1995; 96: 2882-91.
43. Walldius G, Jungner I,. The apoB/apoA-1 ratio: a strong, new risk factor for cardiovascular disease and a target for lipid-lowering therapy-a review of the evidence. J Intern Med 2006; 259: 493-519.